Aurobindo Pharma Slapped With Rs 11 Crore GST Demand, Plans Appeal
Hyderabad: Aurobindo Pharma has been hit with a Rs 11 crore GST demand by Andhra Pradesh authorities, accusing the company of overstating its Input Tax Credit (ITC) for the financial years 2017-18 to 2019-20, along with interest.
The Additional Commissioner (ST), Appellate Authority, Vijayawada, Andhra Pradesh, has sent a notice to the drugmaker demanding the reversal of Input Tax Credit (ITC) and payment of Goods and Services Tax (GST) for the financial years 2017-18 to 2019-20. The total amount in dispute stands at Rs 11.05 crore, including the reversal of ITC amounting to Rs. 5.68 crore, interest of Rs. 4.79 crore, and a penalty of Rs. 56.86 lakh.
The order, passed under the provisions of the Central Goods and Services Tax Act, 2017 and the Andhra Pradesh Goods and Services Tax Act, 2017, alleges that Aurobindo Pharma had claimed excess ITC compared to the GSTR 2A filings and made claims on supplies received from non-filers of GSTR 3B. The company intends to file an appeal before the Tribunal to challenge the decision.
In a statement, Aurobindo Pharma assured investors that the order would not have a material impact on its financials or operations. The company has disclosed the details of the order in accordance with SEBI's (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.